Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.

Lawrence Alan LeiterJosé Luis ZamoranoMaja Bujas-BobanovicMichael J LouieGuillaume LecorpsChristopher P CannonYehuda Handelsman

Published in: Diabetes, obesity & metabolism (2017)

Over a 104-week double-blind study period, alirocumab provided consistently greater LDL-C reductions than ezetimibe, with similar LDL-C results in patients with or without DM. Safety of alirocumab was similar regardless of baseline DM status.

Keyphrases

low density lipoprotein
glycemic control
double blind
type diabetes
placebo controlled
cardiovascular disease
clinical trial
fatty acid
metabolic syndrome
phase iii
skeletal muscle